GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

116 calculators match

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. Cannabinoid Hyperemesis
Functional GI

Cannabinoid Hyperemesis

Rome IV — CVS pattern relieved by cannabis cessation

Prolonged and habitual, typically daily use over years. Occasional use does not fit the pattern.

The confirmatory criterion, and it can only be answered retrospectively after a genuine period of abstinence — typically weeks to months. A diagnosis made before this is provisional.

Identical in pattern to cyclic vomiting syndrome. What defines it is prolonged cannabis use and — the one criterion that cannot be shortcut — relief of the episodes by sustained cessation.

When to use
Use it in any patient presenting with recurrent stereotypical vomiting episodes who uses cannabis regularly, which in practice means asking every patient with this pattern about cannabis rather than waiting for it to be volunteered. The criteria are most useful in emergency and acute medical settings, where these patients present repeatedly, are investigated repeatedly, and are frequently discharged with no diagnosis. It should be applied as a working diagnosis at presentation and confirmed later, since the cessation criterion is retrospective. It does not apply where cannabis use is occasional, or where the vomiting pattern is continuous rather than episodic.
Why use it
Because the diagnosis is otherwise made late, expensively, and often not at all. These patients cycle through emergency departments with recurrent intractable vomiting, accumulate CT scans and endoscopies, and are commonly labelled with cyclic vomiting syndrome — which is clinically identical and for which the treatment does not include the one intervention that works here. Cannabis use is frequently not asked about, and when asked is often under-reported, partly because patients have noticed that cannabis relieves nausea acutely and therefore do not suspect it as the cause. Naming the syndrome converts a recurrent unexplained presentation into a treatable one, and the treatment is free.
Formula, evidence and interpretation

About the Rome IV Criteria for Cannabinoid Hyperemesis Syndrome

One of the three criteria can only be checked backwards, and that is the point. Rome IV requires stereotypical episodic vomiting resembling cyclic vomiting syndrome in onset, duration and frequency; presentation after prolonged cannabis use; and relief of the vomiting episodes by sustained cessation of cannabis. The third is confirmatory and cannot be assessed until a genuine period of abstinence has happened, so a diagnosis made at first presentation is provisional by construction. A supportive but non-essential feature is pathological bathing behaviour — prolonged hot baths or showers that relieve the symptoms.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

Cannabinoid hyperemesis syndrome = ALL of: stereotypical episodic vomiting resembling cyclic vomiting syndrome in onset, duration and frequency AND presentation after prolonged excessive cannabis use AND relief of episodes by sustained cessation of cannabis AND criteria fulfilled for the last 3 months, onset at least 6 months ago Supportive: pathological bathing behaviour (hot showers or baths)
Prolonged excessive use
Rome IV does not quantify this. In practice it means regular, usually daily, use over months to years.
Relief by sustained cessation
Diagnostic but slow. Improvement can take weeks to months, so a brief abstinence trial that fails does not exclude the diagnosis.
Pathological bathing behaviour
Compulsive hot showering or bathing, listed as a supportive remark rather than a criterion — but the feature most likely to give the diagnosis away.
  • Rome IV defines this in terms of the cyclic vomiting criteria and then adds exposure and response to cessation.
  • Response to cessation is diagnostic but slow — improvement can take weeks to months, so a short abstinence trial that fails does not exclude it.

Interpreting the result

At first presentation, a patient with the right pattern and a heavy cannabis history should be managed as having this syndrome while the diagnosis is recorded as provisional. The treatment is complete cessation — not reduction, which does not work, and the distinction is worth stating explicitly because patients commonly try cutting down first and conclude the diagnosis is wrong when it fails. Expect a lag: symptoms may take weeks to months to settle after stopping, so relapse within that window is expected rather than disconfirming. For the acute episode, conventional anti-emetics perform poorly; topical capsaicin and haloperidol or droperidol have better supporting evidence, and hot showers, which patients often use already, are effective symptomatically. Ask about the bathing behaviour directly — patients rarely volunteer it and frequently find it embarrassing, yet it is one of the more distinctive supportive features. Where the pattern fits and there is no cannabis exposure, the assessment moves to cyclic vomiting syndrome, and the management differs substantially.

ScoreBandWhat it meansAction
All three criteria metCannabinoid hyperemesis syndromeConfirmed by relief on sustained cessation — the one finding that distinguishes this from cyclic vomiting syndromeSupport continued abstinence; treat relapse episodes with capsaicin or haloperidol rather than conventional anti-emetics
Pattern and exposure fit, cessation untestedProvisional — awaiting a period of abstinenceThe working diagnosis at first presentation, since the confirmatory criterion is retrospectiveManage as cannabinoid hyperemesis, arrange cessation support, and review after sustained abstinence
No cannabis exposureCriteria not metThe pattern alone is cyclic vomiting syndrome; cannabis exposure is what makes this a distinct disorderAssess for cyclic vomiting syndrome instead

What the Cannabinoid Hyperemesis needs (4 inputs)

Timing
Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis.
Stereotypical episodic vomiting resembling cyclic vomiting syndrome in onset, duration and frequency
The pattern is borrowed wholesale from cyclic vomiting syndrome: acute onset, episodes lasting under a week, stereotypical from one occurrence to the next, with well periods between. Nothing about the vomiting itself distinguishes the two disorders.
Presentation after prolonged use of cannabis
Prolonged and habitual — typically daily use over a period of years. Occasional or recent use does not fit, and the paradox that cannabis relieves nausea acutely means patients often do not connect it to the illness themselves.
Relief of vomiting episodes by sustained cessation of cannabis use
The confirmatory criterion, assessable only in retrospect after genuine abstinence, typically over weeks to months. Until it is satisfied the diagnosis remains provisional, and the calculator reports that state separately rather than forcing a binary.

What it returns

Criteria met, provisional, or not met
Three states rather than two. Where the pattern and exposure fit but cessation has not been tested, the result is reported as provisional — which is the honest position at first presentation.
What remains outstanding
Named explicitly, so it is clear whether the missing element is a clinical feature or simply the passage of time under abstinence.

How it is calculated

The criteria are constructed as a pattern, an exposure and a challenge. The pattern is deliberately identical to cyclic vomiting syndrome, because the two are clinically indistinguishable during an episode — Rome IV does not attempt to separate them on symptoms and says so by defining one in terms of the other. The exposure narrows the field. The challenge, relief on sustained cessation, is what actually establishes causation, and it is as close to a de-challenge experiment as clinical medicine gets outside drug reactions. That structure is unusual among the Rome criteria, most of which are cross-sectional, and it is why this diagnosis behaves differently in practice: it cannot be completed in a single encounter. The proposed mechanism involves chronic cannabinoid receptor stimulation altering thermoregulation and gastric motility, which is also the leading explanation for the compulsive hot bathing that many patients discover for themselves.

Facts & figures

Cannabinoid hyperemesis versus cyclic vomiting syndrome
FeatureCannabinoid hyperemesisCyclic vomiting syndrome
Episode patternIdenticalIdentical
Cannabis exposureProlonged, habitual — requiredNot required
Response to sustained cessationResolves — the confirmatory criterionUnchanged
Compulsive hot bathingSupportive feature, commonUncommon
Migraine historyNot part of the criteriaSupportive remark in Rome IV
Effective treatmentComplete cannabis cessationAbortive plus prophylactic therapy, often migraine-directed

Rome IV defines cannabinoid hyperemesis in terms of cyclic vomiting syndrome precisely because nothing about the episodes themselves separates them. Only the exposure history and the response to stopping do.

Acute management, where the usual approach underperforms
InterventionNote
Topical capsaicinApplied to the abdomen; better supporting evidence than conventional anti-emetics
Haloperidol or droperidolBetter evidence than ondansetron in this syndrome specifically
Hot showers or bathsEffective symptomatically; many patients have already discovered this themselves
Conventional anti-emeticsPerform poorly — a common source of the impression that the episode is refractory
Fluids and electrolyte correctionSupportive care remains necessary

The poor response to standard anti-emetics is itself a clue, and one that frequently leads to further investigation rather than to the diagnosis.

Evidence

Derivation — Rome Foundation, gastroduodenal disorders committee

2016

Consensus criteria from the Rome IV gastroduodenal disorders committee, which introduced cannabinoid hyperemesis syndrome as a named disorder distinct from cyclic vomiting syndrome.

Consensus-derived. Rome IV defines the disorder in terms of cyclic vomiting syndrome for the pattern, and adds exposure and response to cessation as the distinguishing criteria. Pathological bathing behaviour is listed as a supportive remark rather than a requirement.

Overlap with cyclic vomiting syndrome

2019

Published comparisons of cyclic vomiting syndrome and cannabinoid hyperemesis syndrome in patients with chronic cannabis use, examining which features distinguish them.

Support the position that the syndromes cannot be separated on episode characteristics, and that sustained cessation with resolution is the only finding approaching a pathognomonic sign.

Management guidance — ANMS/ACG cyclic vomiting guideline

2019

Guidelines on the management of cyclic vomiting syndrome in adults from the American Neurogastroenterology and Motility Society, which address cannabinoid hyperemesis alongside it.

Recommend assessment of cannabis use in all patients presenting with a cyclic vomiting pattern, and cessation as the primary intervention where cannabinoid hyperemesis is suspected.

How it compares

Cannabinoid Hyperemesis vs Cyclic vomiting syndrome

Clinically indistinguishable during an episode — Rome IV defines this one in terms of the other, and only cannabis exposure and response to cessation separate them.

The episodes are identical in onset, duration, frequency and character, which is why Rome IV does not attempt a symptom-based separation. What differs is everything around them: a prolonged cannabis history, the compulsive hot bathing many patients adopt, and above all resolution on sustained abstinence. The practical consequence is large — cyclic vomiting syndrome is managed with abortive and prophylactic therapy, often migraine-directed, while cannabinoid hyperemesis is managed by stopping cannabis, and neither approach helps much in the other condition. Any patient meeting cyclic vomiting criteria should be asked about cannabis before that label is settled.

Open the Cyclic vomiting syndrome calculator →Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019;31 Suppl 2:e13604.

Cannabinoid Hyperemesis vs Chronic nausea and vomiting syndrome

Distinguished by pattern rather than cause — cannabinoid hyperemesis is episodic with well periods, while chronic nausea and vomiting syndrome is continuous or near-continuous.

Cannabis can produce chronic nausea as well as the hyperemetic pattern, so exposure alone does not settle which disorder is present. The discriminator is the shape of the illness over time: discrete stereotypical episodes with symptom-free intervals point to cannabinoid hyperemesis, whereas persistent day-to-day nausea at least one day a week, or weekly vomiting without an episodic structure, meets the chronic nausea and vomiting criteria instead. Both warrant a cannabis history and both may improve on cessation, but only the episodic form carries the formal diagnosis.

Open the Chronic nausea and vomiting syndrome calculator →

Pearls & pitfalls

  • Ask every patient with a cyclic vomiting pattern about cannabis, and ask about quantity and duration rather than accepting a yes or no.
  • Patients frequently do not suspect cannabis, because it relieves nausea acutely. Many increase their use as the illness worsens, which conceals the relationship further.
  • Cutting down does not work. Only complete, sustained cessation resolves the syndrome, and this needs stating explicitly or patients will try reduction and conclude the diagnosis is wrong.
  • Expect a lag of weeks to months after stopping before episodes settle. Relapse within that window is expected and should not be read as disconfirming the diagnosis.
  • The diagnosis is provisional until cessation has been tested. Recording it as established at first presentation overstates what the criteria permit.
  • Conventional anti-emetics perform poorly. Their failure is often what prompts further investigation instead of the diagnosis.
  • Ask about hot bathing directly — it is highly characteristic, patients rarely volunteer it, and many find it embarrassing.
  • Cannabis potency has risen substantially since these criteria were written, and presentations now occur after shorter exposure than the classic description implies.
  • Offer cessation support rather than only advice to stop; dependence is common in this group and advice alone frequently fails.
  • Legality varies and patients may be guarded. Asking without judgement materially improves disclosure.

Critical actions

  • Take a detailed cannabis history — frequency, duration, route and recent changes — in every patient with recurrent stereotypical vomiting.
  • Ask specifically about compulsive hot bathing or showering for symptom relief.
  • Record the diagnosis as provisional at first presentation and state plainly what would confirm it.
  • Explain that complete cessation, not reduction, is the treatment, and that improvement may take weeks to months.
  • Use topical capsaicin, or haloperidol or droperidol, for acute episodes in preference to conventional anti-emetics.
  • Correct fluid and electrolyte disturbance; the vomiting can be severe enough to cause significant depletion.
  • Refer for cannabis cessation support rather than relying on advice alone.
  • Review after a genuine period of abstinence to confirm or refute the diagnosis, and reassess for cyclic vomiting syndrome if episodes continue.

Why this score exists

Including this as a named disorder was a decision about clinical utility rather than mechanism. The committee could not distinguish the syndrome from cyclic vomiting syndrome on any feature of the episodes, and said so by defining it in those terms — but the treatment differs so completely that grouping them would have been actively harmful. The choice to make relief on cessation a criterion rather than a supportive feature is the interesting part: it builds a de-challenge into the diagnostic definition, which means the diagnosis is inherently longitudinal and cannot be completed in an emergency department. That is uncomfortable for a criteria set intended partly for acute settings, and it is the reason a provisional category is needed in practice even though Rome IV does not formally provide one. The bathing behaviour was left as a supportive remark rather than promoted to a criterion, despite being highly characteristic, because it is a learned response rather than a feature of the disease.

About the creator

  • Vincenzo Stanghellini

    First author, Rome IV gastroduodenal disorders committee

    Chaired the committee that introduced cannabinoid hyperemesis syndrome into the Rome classification.

  • William L. Hasler

    Co-author; nausea and vomiting disorders

    Co-authored the Rome IV gastroduodenal chapter, including the nausea and vomiting disorders section.

Limitations

  • The confirmatory criterion is retrospective, so the diagnosis cannot be completed at the presentation where it matters most — in an acute setting with a vomiting patient.
  • Rome IV provides no formal provisional category, despite the diagnosis being inherently longitudinal.
  • 'Prolonged use of cannabis' is not quantified, and rising product potency means presentations now occur after shorter exposure than the original descriptions suggest.
  • Relies on accurate disclosure of cannabis use, which is affected by legality, stigma and the patient's own belief that cannabis is helping.
  • Indistinguishable from cyclic vomiting syndrome on any feature of the episodes, so misclassification is inevitable in patients who use cannabis and have genuine cyclic vomiting syndrome.
  • A consensus definition with no validation cohort — the diagnosis is confirmed only retrospectively, by whether symptoms stop after sustained cessation.
  • Says nothing about severity, and episodes range from troublesome to requiring admission for dehydration and electrolyte disturbance.
  • The evidence base for acute treatment is limited and largely observational, though consistent in showing conventional anti-emetics perform poorly.

If you are the patient

Cannabinoid hyperemesis syndrome means repeated episodes of severe vomiting caused by long-term regular cannabis use. The episodes come on suddenly, last up to a few days, and between them you feel well — then the pattern repeats. Many people find that long hot showers or baths are the only thing that eases it, which is a very characteristic feature and worth mentioning to your doctor even though it can feel odd to bring up. The confusing part is that cannabis usually settles nausea in the short term, so it rarely occurs to people that it might be the cause — and many end up using more as the episodes get worse, which makes things worse still. The only treatment that works is stopping cannabis completely. Cutting down is not enough, and this is the point people most often get stuck on. It is also important to know that improvement is not immediate: it can take weeks or even a few months after stopping before the episodes settle, so having another episode soon after quitting does not mean the diagnosis is wrong or that stopping was pointless. If quitting is difficult, ask for proper support rather than trying alone — dependence is common and help is available. During an episode, standard anti-sickness medicines often do not work well, and your doctor may use different treatments instead.

Frequently asked questions

What are the Rome IV criteria for cannabinoid hyperemesis syndrome?#

Stereotypical episodic vomiting resembling cyclic vomiting syndrome in onset, duration and frequency; presentation after prolonged cannabis use; and relief of the vomiting episodes by sustained cessation of cannabis. All must be fulfilled for three months with onset at least six months earlier. Pathological bathing behaviour is a supportive remark, not a requirement.

How is cannabinoid hyperemesis different from cyclic vomiting syndrome?#

Not by the episodes — Rome IV defines cannabinoid hyperemesis in terms of cyclic vomiting syndrome precisely because they are clinically indistinguishable during an attack. The differences are prolonged cannabis exposure, the compulsive hot bathing many patients adopt, and resolution on sustained cessation. That last point is the only finding approaching a pathognomonic sign.

Why does hot bathing relieve cannabinoid hyperemesis?#

The leading explanation involves chronic cannabinoid receptor stimulation disrupting thermoregulation, with hot water providing relief through that pathway. It is listed in Rome IV as a supportive remark rather than a criterion, because it is a learned behaviour rather than a feature of the disease itself — but it is highly characteristic, and worth asking about directly since patients rarely volunteer it.

Does cutting down on cannabis help?#

No. Only complete, sustained cessation resolves the syndrome, and this is worth stating explicitly because patients commonly attempt reduction first, find it does not work, and conclude the diagnosis must be wrong. The criteria specify sustained cessation for exactly this reason.

How long after stopping cannabis do symptoms improve?#

Typically weeks to months rather than days. That lag matters clinically: a relapse in the early period after stopping is expected and should not be interpreted as disconfirming the diagnosis or as evidence that cessation was pointless. Patients need to be warned about it in advance or they frequently resume use.

Can cannabinoid hyperemesis be diagnosed at first presentation?#

Only provisionally. The confirmatory criterion — relief on sustained cessation — can only be assessed after a genuine period of abstinence, so a diagnosis made in an emergency department is a working one by construction. The right approach is to manage as cannabinoid hyperemesis, record it as provisional, and review after abstinence.

What treats an acute cannabinoid hyperemesis episode?#

Conventional anti-emetics perform poorly, and their failure is often what prompts further investigation instead of the diagnosis. Topical capsaicin applied to the abdomen, and haloperidol or droperidol, have better supporting evidence. Hot showers help symptomatically. Fluid and electrolyte correction remains necessary, as the vomiting can cause significant depletion.

How much cannabis use is 'prolonged'?#

Rome IV does not quantify it, describing only prolonged use — classically daily use over years. This is a genuine limitation, and rising product potency means presentations now occur after shorter and lighter exposure than the original descriptions imply. Take a detailed history of frequency, duration and any recent change rather than applying a fixed threshold.

Related calculators

  • Cyclic Vomiting Syndrome — Rome IV — stereotypical episodic vomiting
  • Chronic Nausea & Vomiting — Rome IV — chronic nausea and vomiting syndrome
  • Rumination Syndrome — Rome IV — effortless regurgitation without retching
  • Functional Dyspepsia — Rome IV — with PDS and EPS subtyping
  • CAGE — Alcohol use disorder screening (4 questions)

References

Original / primary reference

  1. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, Talley NJ. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-1392 (Rome IV).

Clinical practice guidelines

  1. Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019;31 Suppl 2:e13604.

Systematic review

  1. Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment — a Systematic Review. J Med Toxicol. 2017;13(1):71-87.

Last updated July 31, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.